British pharma giant GSK to acquire US drug developer IDRx in $1.15 billion deal




The biopharmaceutical company’s drug in development is designed to treat gastrointestinal stromal tumors (GIST). Read More



Source link

  • Related Posts

    Beacon Building Products to Host 2025 Investment Day Via Investing.com

    HERNDON, Va.–(BUSINESS WIRE)–Beacon (Nasdaq: BECN) the leading publicly-traded specialty wholesale distributor of roofing, waterproofing and related outdoor products announced today that it will host the an Investor Day in New…

    Enveric Biosciences announces offering of common shares and warrants

    Enveric Biosciences announces offering of common shares and warrants Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *